Eckert & Ziegler stock awaits earnings test after Ac-225 approval
Published on 11/06/2026 at 17:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegulatory progress meets earnings test
- GMP authorization supports clinical supply plans for the radioisotope platform.
- The production route links radium irradiation in the Czech Republic with processing in Braunschweig.
- A commercial-scale facility in China is planned to move toward initial operations in early 2027.
Eckert & Ziegler stock has moved lower since the previous report, while the company remains focused on turning its Actinium-225 production capability into clinical and future commercial supply. The next quarterly report is scheduled for November 12.
The stock traded at 13.79 euros on Lang & Schwarz at 17:40 CET on Friday, November 6, 2026, 0.22 percent below the Xetra close of Friday, November 6, at 13.82 euros. Compared with the 14.18-euro Lang & Schwarz quote cited in the previous report on Thursday, November 5, at 10:33 CET, the newer quote is 2.75 percent lower.
GMP approval strengthens supply platform
According to the Eckert & Ziegler EQS News announcement published on October 28, Eckert & Ziegler Therapeutics GmbH received manufacturing authorization for Actinium-225 under Good Manufacturing Practice standards. The wholly owned subsidiary can use the certified process for material intended for investigational patient treatments.
The production route starts with cyclotron-based irradiation of Radium-226 at the Czech Academy of Sciences' Nuclear Physics Institute in the Czech Republic. The irradiated material is then processed at Eckert & Ziegler's Braunschweig site. The company said its process limits long-lived impurities and recovers unconverted Radium-226 for repeated use.
Capacity plans remain ahead
A joint-venture facility in Jintan, China, is intended to become the country's first commercial-scale Actinium-225 production site. Initial operations are planned for early 2027, followed by a second phase. Additional capacity near Boston and in Germany remains under consideration.
The regulatory milestone improves the production basis for clinical programs, but its financial effect will depend on output volumes, customer commitments and commercial adoption. Eckert & Ziegler's real-time quote of Eckert & Ziegler stock remains the direct market reference.
Eckert & Ziegler operates in medical and isotope products; its investor page describes applications in cancer therapy, industrial radiometry and nuclear-medicine diagnostics and therapy.
The DAX provides the relevant German market backdrop.
More news and analyses on Eckert & Ziegler stock will follow the November 12 results and the next capacity milestones.
Eckert & Ziegler SE
- ISIN: DE0005659700
- Ticker: EUZ.DE
- Exchange: Xetra
- Lang & Schwarz quote: 13.79 euros, Friday, November 6, 2026, 17:40 CET
- Xetra close: 13.82 euros, Friday, November 6, 2026
- Change versus Xetra close: -0.22 percent
- 52-week range: 11.91 to 17.47 euros
- Market capitalization: 864.81 million euros
- Index: TecDAX
